Drug Co. Investors Seek OK For Early $3.8M Settlement

Law360, New York (April 17, 2017, 2:55 PM EDT) -- A putative class of investors in Amicus Therapeutics Inc. who said the company’s misleading statements about their interaction with the U.S. Food and Drug Administration amounted to securities fraud asked a New Jersey federal court on Friday to approve a $3.75 million settlement that would end the litigation before the court even considered dismissal.

The shareholders said their deal with Amicus would get them more than 8 percent of the $44 million in damages they say they incurred in the last two weeks of September 2015,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.